Talaris Therapeutics to Present at William Blair’s Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) — Talaris Therapeutics, Inc. (Nasdaq:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at William Blair’s Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on Wednesday, September 28, 2022 at 1:00 PM ET.
Related news for (TALS)
- TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. – TALS
- TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. – TALS
- Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update
- Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial